A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug

BACKGROUND AND PURPOSE: ATB‐346 is a hydrogen sulfide (H(2)S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Pharmacol
Hlavní autoři: Wallace, John L., Nagy, Peter, Feener, Troy D., Allain, Thibault, Ditrói, Tamás, Vaughan, David J., Muscara, Marcelo N., de Nucci, Gilberto, Buret, Andre G.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Themed Section: Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7024706/
https://ncbi.nlm.nih.gov/pubmed/30834513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14641
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky